| Identification | Back Directory | [Name]
MEOSUC-ALA-PHE-LYS-AMC TFA | [CAS]
201853-92-1 | [Synonyms]
MeOSuc-AFK-AMC
MeOSuc-Ala-Phe-Lys-AMC
MEOSUC-ALA-PHE-LYS-AMC TFA
L-Lysinamide,N-(4-methoxy-1,4-dioxobutyl)-L-alanyl-L-phenylalanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-,mono(trifluoroacetate)
methyl 4-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate | [Molecular Formula]
C35H42F3N5O10 | [MDL Number]
MFCD00152192 | [MOL File]
201853-92-1.mol | [Molecular Weight]
749.73 |
| Hazard Information | Back Directory | [Uses]
MeOSuc-Ala-Phe-Lys-AMC TFA is a peptide substrate of plasmin[1]. | [References]
[1] Dall jl, et, al. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc Res. 2010 Jan 1;85(1):184-93. DOI:10.1093/cvr/cvp253 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|